Syndax Pharmaceuticals Inc (SNDX) is a publicly traded company in the Unknown sector. Across all available filings, 22 corporate insiders have executed 280 transactions totaling $54.2M, demonstrating a bearish sentiment with -$49.5M in net insider flow. The most recent transaction on Feb 9, 2026 involved a sale of 3,410 shares valued at $71.7K.
No significant insider buying has been recorded for SNDX in the recent period.
No significant insider selling has been recorded for SNDX in the recent period.
Based on recent SEC filings, insider sentiment for SNDX is bearish with an Insider Alignment Score of 4/100 and a net flow of -$49.5M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Syndax Pharmaceuticals Inc (SNDX) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 22 insiders are actively trading SNDX stock, having executed 280 transactions in the past 90 days. The most active insider is Briggs Morrison (Executive), who has made 56 transactions totaling $36.6M.
Get notified when executives and directors at SNDX file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Feb 9, 2026 | A. Goldan Keith | Chief Financial Officer | Sale | 3,410 | $21.03 | $71.7K | C-Suite |
| Feb 9, 2026 | A. Metzger Michael | Executive | Sale | 17,159 | $21.03 | $360.8K | |
| Dec 1, 2025 | A. Goldan Keith | Executive | Gift | 1,224 | $N/A | $0 | |
| Sep 8, 2025 | A. Metzger Michael | Executive | Option Exercise | 157,307 | $10.90 | $1.7M | Large |
| Sep 8, 2025 | A. Metzger Michael | Executive | Sale | 157,307 | $16.41 | $2.6M | Large |
| Aug 18, 2025 | Podlesak Dennis | Executive | Option Exercise | 19,200 | $7.20 | $138.2K | |
| Aug 18, 2025 | Podlesak Dennis | Executive | Sale | 19,200 | $15.84 | $304.1K | |
| Aug 15, 2025 | Podlesak Dennis | Executive | Option Exercise | 19,200 | $7.20 | $138.2K | |
| Aug 15, 2025 | Podlesak Dennis | Executive | Sale | 19,200 | $15.54 | $298.4K | |
| Aug 14, 2025 | Podlesak Dennis | Executive | Option Exercise | 19,200 | $7.20 | $138.2K | |
| Aug 14, 2025 | Podlesak Dennis | Executive | Sale | 19,200 | $14.19 | $272.4K | |
| Jul 31, 2025 | A. Goldan Keith | Executive | Other | 1,226 | $8.43 | $10.3K | |
| Jul 16, 2025 | A. Metzger Michael | Executive | Sale | 7,534 | $9.29 | $70.0K | |
| Jul 16, 2025 | A. Goldan Keith | Executive | Sale | 1,296 | $9.29 | $12.0K | |
| Jun 14, 2024 | A. Goldan Keith | Executive | Purchase | 1,250 | $20.03 | $25.0K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 103 | $51.8M | 68.2% |
Exercise(M) | 95 | $19.8M | 26.1% |
Purchase(P) | 12 | $2.3M | 3.1% |
Disposition(D) | 1 | $1.7M | 2.3% |
Other(J) | 20 | $227.2K | 0.3% |
Gift(G) | 1 | $0 | 0.0% |
Award(A) | 35 | $0 | 0.0% |
Conversion(C) | 13 | $0 | 0.0% |
Insider selling pressure at Syndax Pharmaceuticals Inc has increased, with 22 insiders executing 280 transactions across all time. Total sales of $51.8M significantly outpace purchases of $2.3M, resulting in a net outflow of $49.5M. However, 36% of these transactions are pre-scheduled 10b5-1 plans, often used for tax planning or diversification rather than signaling negative outlook.